Aegerion Pharmaceuticals (AEGR) Halted on FDA Approval News
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Analyst Bullish as Aegerion (AEGR) Drug Approved with Broad Label
December 26, 2012 9:23 AM ESTOn Monday Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) announced that the U.S. Food & Drug Administration approved JUXTAPID (lomitapide) capsules as an adjunct to a low-fat diet and other lipid-lowering treatments. In response, Leerink Swann reiterated an Outperform rating on Aegerion and raised its price target to $30.00 (from $25.00).
"Lead agent Juxtapid (lomitapide) is a smallmolecule microsomal triglyceride transfer protein (MTP) inhibitor with the unique ability to limit... More
Aegerion (AEGR) Receives FDA Approval for JUXTAPID Caps
December 24, 2012 7:01 AM ESTAegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) announced that the U.S. Food & Drug Administration (FDA) has approved JUXTAPID (lomitapide) capsules as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B) and non- high-density-lipoprotein cholesterol (non-HDL) in patients with homozygous familial hypercholesterolemia (HoFH).
"We are excited that JUXTAPID will become a new treatment option for patients with HoFH," said Marc Beer, Chief Executive Officer at Aegerion. "The approval of our first product also marks an important... More
